FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for UrticariaZacks Investment Research • Monday
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticariaGlobeNewsWire • 11/15/24
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaGlobeNewsWire • 11/14/24
Healx announces agreement with Sanofi to seek new rare disease indications for compound using AI drug discovery platformBusiness Wire • 11/13/24
Sanofi: Diverse Drug Portfolio And Future Pipeline, 4% Dividend Yield Looks AttractiveSeeking Alpha • 11/13/24
The Accumulus Platform Powers Sanofi's Submissions to Multiple Regulators Around the WorldGlobeNewsWire • 11/07/24
Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitisGlobeNewsWire • 11/06/24
Sanofi Q3 Earnings Beat, Dupixent, New Drugs, Vaccines Drive SalesZacks Investment Research • 10/25/24
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly BeatInvestors Business Daily • 10/25/24
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 ForecastBenzinga • 10/25/24
Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performanceGlobeNewsWire • 10/25/24
Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAIGlobeNewsWire • 10/24/24
Sanofi Negotiating Exclusively With CD&R for Opella 50% Stake SaleZacks Investment Research • 10/21/24
Press Release: Sanofi and CD&R partner to fuel Opella's ambitions in consumer healthcareGlobeNewsWire • 10/21/24